

A Case-Based Roadmap for Improved Patient Outcomes in Plaque Psoriasis



REFERENCES

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. *J Am Acad Dermatol*. 2014;70(3):512-516. doi:10.1016/j.jaad.2013.11.013
2. Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. *Am Health Drug Benefits*. 2016;9(9):504-513.
3. Elms CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087
4. Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: Consensus recommendations. *Dermatol Ther (Heidelb)*. 2021;11(1):235-252. doi:10.1007/s13555-020-00475-8
5. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. *J Am Acad Dermatol*. 2017;76(2):290-298. doi:10.1016/j.jaad.2016.10.017
6. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res*. 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1
7. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. *J Eur Acad Dermatol Venereol*. 2010;24 Suppl 2:10-16. doi:10.1111/j.1468-3083.2009.03562.x
8. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. *Br J Dermatol*. 2006;155(4):707-713. doi:10.1111/j.1365-2133.2006.07389.x
9. Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment goals in psoriasis: Which outcomes matter most? *Am J Clin Dermatol*. 2020;21(4):505-511. doi:10.1007/s40257-020-00521-3
10. Dopytalska K, Sobolewski P, Blaszczyk A, Szymanska E, Walecka I. Psoriasis in special localizations. *Reumatologia*. 2018;56(6):392-398. doi:10.5114/reum.2018.80718
11. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. *J Dermatolog Treat*. 2013;24(5):356-360. doi:10.3109/09546634.2012.742950
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x
13. Karreman MC, Weel A, van der Ven M, et al. Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. *Rheumatology (Oxford)*. 2017;56(4):597-602. doi:10.1093/rheumatology/kew410
14. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. *J Cutan Med Surg*. 2003;7(3):185-192. doi:10.1007/s10227-002-0114-5
15. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. *J Dermatol Treat*. 2018;29(2):111-115.
16. Johnson MC, Heron CE, Ghamrawi RI, Balogh EA, Feldman SR. Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials. *J Psoriasis Psoriatic Arthritis*. 2021;6(2):99-105. doi:10.1177/2475530321999087
17. Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. *Dermatol Ther (Heidelb)*. 2019;9(1):5-18. doi:10.1007/s13555-018-0279-5
18. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057
19. Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. *J Am Acad Dermatol*. 2016;75(3):612-618 e616. doi:10.1016/j.jaad.2016.02.1221
20. Ozkur E, Kivanc Altunay I, Oguz Topal I, et al. Switching biologics in the treatment of psoriasis: A multicenter experience. *Dermatology*. 2021;237(1):22-30. doi:10.1159/000504839
21. Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. *J Eur Acad Dermatol Venereol*. 2017;31(4):679-685. doi:10.1111/jdv.13990
22. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of switching to ixekizumab in etanercept non-responders: A subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3). *Am J Clin Dermatol*. 2017;18(2):273-280. doi:10.1007/s40257-016-0246-9
23. Warren RB, Barker J, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE). *Br J Dermatol*. 2020;183(1):60-70. doi:10.1111/bjd.18623
24. Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. *Dermatol Ther*. 2015;28(6):390-403. doi:10.1111/dth.12267
25. Albanesi C. Immunology of Psoriasis. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, eds. *Clin Immunol*. Elsevier; 2019:871-878.e871. <https://www.sciencedirect.com/science/article/pii/B9780702068966000648>
26. Singh D, Ravi A, Southworth T. CRTH2 antagonists in asthma: current perspectives. *Clin Pharmacol*. 2017;9:165-173. doi:10.2147/CPAA.S119295

27. Junttila IS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. *Front Immunol.* 2018;9(888):888. doi:10.3389/fimmu.2018.00888
28. West EE, Kashyap M, Leonard WJ. TSLP: A Key Regulator of Asthma Pathogenesis. *Drug Discov Today Dis Mech.* 2012;9(3-4):10.1016/j.ddmec.2012.1009.1003. doi:10.1016/j.ddmec.2012.09.003
29. Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. *Front Immunol.* 2020;11(1894):1894. doi:10.3389/fimmu.2020.01894
30. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. *Lancet.* 2021;397(10273):475-486. doi:10.1016/s0140-6736(21)00126-4
31. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. *N Engl J Med.* 2021;385(2):142-152. doi:10.1056/NEJMoa2102383
32. Hot A, Zrioual S, Toh ML, Lenief V, Miossec P. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. *Ann Rheum Dis.* 2011;70(2):341-348. doi:10.1136/ard.2010.132233
33. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. *Br J Dermatol.* 2009;160(2):319-324. doi:10.1111/j.1365-2133.2008.08902.x
34. van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? *Arthritis Res Ther.* 2014;16(4):426. doi:10.1186/s13075-014-0426-z
35. Al-Hammadi A, Ruszczak Z, Magarinos G, Chu CY, El Dershaby Y, Tarcha N. Intermittent use of biologic agents for the treatment of psoriasis in adults. *J Eur Acad Dermatol Venereol.* 2021;35(2):360-367. doi:10.1111/jdv.16803
36. Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: A phase 3 randomized clinical trial. *JAMA Dermatol.* 2020;156(6):649-658. doi:10.1001/jamadermatol.2020.0723
37. Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. *J Invest Dermatol.* 2019;139(12):2437-2446 e2431. doi:10.1016/j.jid.2019.05.016
38. Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. *J Eur Acad Dermatol Venereol.* 2019;33(3):568-576. doi:10.1111/jdv.15292
39. Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). *Br J Dermatol.* 2020;183(6):1037-1048. doi:10.1111/bjd.19132
40. Kim B, Maverakis E, Raychaudhuri SP. Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission? *Ann Dermatol.* 2019;31(5):495-501. doi:10.5021/ad.2019.31.5.495
41. Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. *Br J Dermatol.* 2019;180(5):1069-1076. doi:10.1111/bjd.16776
42. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol.* 2007;56(1):31 e31-15. doi:10.1016/j.jaad.2006.07.017
43. Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. *J Eur Acad Dermatol Venereol.* 2017;31(6):1004-1013. doi:10.1111/jdv.14163
44. Secukinumab retreatment shows rapid recapture of treatment response: An analysis of a phase 3 extension trial in psoriasis. *J Am Acad Dermatol.* 2017;76(6):AB232. doi:10.1016/j.jaad.2017.04.900
45. Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. *Br J Dermatol.* 2009;161(5):1190-1195. doi:10.1111/j.1365-2133.2009.09238.x
46. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet.* 2008;371(9625):1665-1674. doi:10.1016/S0140-6736(08)60725-4
47. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. *J Am Acad Dermatol.* 2017;76(1):60-69 e69. doi:10.1016/j.jaad.2016.08.008
48. Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. *J Am Acad Dermatol.* 2018;78(4):741-748. doi:10.1016/j.jaad.2017.10.025
49. Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. *J Eur Acad Dermatol Venereol.* 2021;35(2):450-457. doi:10.1111/jdv.16816
50. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet.* 2015;386(9993):541-551. doi:10.1016/S0140-6736(15)60125-8
51. Yamazaki F. Psoriasis: Comorbidities. *J Dermatol.* 2021;48(6):732-740. doi:10.1111/1346-8138.15840
52. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. *Dermatology.* 2012;225(2):121-126. doi:10.1159/000342180
53. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006;296(14):1735-1741. doi:10.1001/jama.296.14.1735
54. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. *J Invest Dermatol.* 2009;129(10):2411-2418. doi:10.1038/jid.2009.112
55. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;73(24):3168-3209.
56. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. *J Am Acad Dermatol.* 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058

57. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *Arch Dermatol*. 2012;148(11):1244-1250. doi:10.1001/archdermatol.2012.2502
58. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. *J Eur Acad Dermatol Venereol*. 2010;24(5):548-554. doi:10.1111/j.1468-3083.2009.03463.x
59. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. *N Engl J Med*. 2017;376(21):2095-2096. doi:10.1056/NEJMc1704342
60. Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. *Reumatologia*. 2017;55(3):131-135. doi:10.5114/reum.2017.68912
61. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29. doi:10.1002/acr.23789
62. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. *Clin Exp Rheumatol*. 2009;27(3):469-474.
63. Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). *Br J Dermatol*. 2013;168(4):802-807. doi:10.1111/bjd.12190
64. Johansen CB, Jimenez-Solem E, Haerskjold A, Sand FL, Thomsen SF. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: A review. *Int J Mol Sci*. 2018;19(5):1349. doi:10.3390/ijms19051349
65. Methotrexate [package insert]. Accessed July 30, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf

